Today’s FY results, slightly ahead of expectations as a result of good operating cost control, highlight a busy period for the company, culminating in a ground-breaking licensing deal with Fosun Pharma for the Chinese market in April. The company’s lead stem cell therapy programmes (CTX for stroke disability and hRPC for ophthalmic disorders) remain on track, with top-line data on all 12 patients in the Phase IIa trial of hRPC in Retinitis Pigmentosa (RP) expected in October. We look forward to ....
11 Jul 2019
FY results ahead on cost control, pipeline development on track
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY results ahead on cost control, pipeline development on track
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
11 Jul 2019 -
Author:
Jens Lindqvist -
Pages:
4
Today’s FY results, slightly ahead of expectations as a result of good operating cost control, highlight a busy period for the company, culminating in a ground-breaking licensing deal with Fosun Pharma for the Chinese market in April. The company’s lead stem cell therapy programmes (CTX for stroke disability and hRPC for ophthalmic disorders) remain on track, with top-line data on all 12 patients in the Phase IIa trial of hRPC in Retinitis Pigmentosa (RP) expected in October. We look forward to ....